CD19 and cancer: In contrast, the CD19-4D5scFv redirected CD19scFv-CAR T cells kill the healthy fibroblasts only in presence of more than 100 ng/mL fusion protein, which is 100-fold higher than the ED50 for ErbB2 cancer cell killing.